Immunome Inc.

Plus: Arbuckle retiring from Vertex, and updates from Lb, Glox, Titan and more

Plus: Day One’s ex-U.S. deal with Ipsen; Novartis taps Dren Bio’s oncology platform; BI buys Avalon-backed Nerio; and Collegium’s ADHD takeout

Plus: Immunome promotes Max Rosett to CFO, and Mark de Jong becomes CTO at Full-Life

Plus: Ipsen names Keira Driansky president of North America, and updates from Immunome and SFA

Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential

Plus: Dyne shares slip with CEO departing, and updates from Ardelyx and ProKidney

Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering

BioCentury’s weekly roundup of biopharma deals

Plus: 4DMT hires Noriyuki Kasahara as CSO, and updates from SV, Omega, AbbVie Ventures, Nikang, Immunome, Wugen, Zevra and Quris

Plus: Nassim Usman at the helm at Totus as it raises $66M series B round, and updates from Tourmaline, HKEX, CIRM, CorMedix and RiverVest